Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

BACKGROUND: Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathways may offer greater antitumor activity compared wi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Med
Autori principali: Harding, James J., Do, Richard K., Yaqubie, Amin, Cleverly, Ann, Zhao, Yumin, Gueorguieva, Ivelina, Lahn, Michael, Benhadji, Karim A., Kelley, Robin K., Abou‐Alfa, Ghassan K.
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2021
Soggetti:
Clinical Cancer Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8085979/
https://ncbi.nlm.nih.gov/pubmed/33811482
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3880
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi